ADMA Biologics (NASDAQ:ADMA) Price Target Raised to $26.00 at HC Wainwright

ADMA Biologics (NASDAQ:ADMA) had its price objective raised by equities research analysts at HC Wainwright from $18.00 to $26.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 14.94% from the stock’s current price. HC Wainwright also issued estimates for ADMA Biologics’ Q4 2024 earnings at $0.19 EPS, FY2024 earnings at $0.55 EPS, Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS and Q4 2025 earnings at $0.24 EPS.

ADMA has been the topic of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $21.25.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $22.62 on Friday. The stock has a market capitalization of $5.27 billion, a PE ratio of 161.57 and a beta of 0.64. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. ADMA Biologics has a 12 month low of $3.60 and a 12 month high of $23.52. The business has a 50 day simple moving average of $18.12 and a 200-day simple moving average of $13.89.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business’s revenue was up 78.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.02) earnings per share. Equities analysts predict that ADMA Biologics will post 0.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the sale, the chief operating officer now directly owns 449,088 shares in the company, valued at approximately $7,589,587.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the transaction, the chief operating officer now owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its holdings in ADMA Biologics by 152.2% in the 1st quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after acquiring an additional 442,315 shares during the last quarter. GSA Capital Partners LLP increased its stake in ADMA Biologics by 707.3% in the first quarter. GSA Capital Partners LLP now owns 134,929 shares of the biotechnology company’s stock valued at $891,000 after purchasing an additional 118,215 shares during the last quarter. LSV Asset Management purchased a new position in ADMA Biologics during the first quarter worth about $1,028,000. Sei Investments Co. boosted its stake in ADMA Biologics by 176.0% in the 1st quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company’s stock worth $2,597,000 after buying an additional 250,925 shares during the last quarter. Finally, Inspire Investing LLC grew its holdings in ADMA Biologics by 125.2% in the 1st quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock valued at $1,249,000 after buying an additional 105,256 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.